Exhibit 99.1 HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.27 Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of ...

Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 millionNet Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 millionGAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.271Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595-$625 million, Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of ...

Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO® and SC through 2032Reiterates 2024 Royalty Revenue Guidance of $520-555 million and Expectations to Generate >$1 billion in 2027Conference Call Scheduled Today, Thursday, October 24 at 5:30am PT/8:30am ETSAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update following a decision by the Opposition Division of the European Patent Office ("EPO") to revoke one of the Jansse ...

SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024, following the close of trading.Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813747.A live webcast and re ...

Core Insights - Halozyme Therapeutics (HALO) is positioned to continue its earnings-beat streak, having surpassed earnings estimates by an average of 15.58% in the last two quarters [1][2]. Earnings Performance - For the most recent quarter, Halozyme reported earnings of $0.91 per share, exceeding the expected $0.78 per share by 16.67%. In the previous quarter, it reported $0.79 per share against an expectation of $0.69 per share, resulting in a surprise of 14.49% [2]. Earnings Estimates - Recent estimates for Halozyme have been increasing, with a positive Earnings ESP of +1.01%, indicating bullish sentiment among analysts regarding the company's earnings prospects [3][6]. Predictive Metrics - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that such combinations lead to positive surprises nearly 70% of the time [4][6]. Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate than earlier predictions [5]. Importance of Earnings ESP - Companies often beat consensus EPS estimates, but this is not the sole reason for share price gains. A negative Earnings ESP does not necessarily indicate an earnings miss, highlighting the importance of checking this metric before quarterly releases [7].

It has been about a month since the last earnings report for Halozyme Therapeutics (HALO) . Shares have added about 14.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Halozyme Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Halozyme's Q2 Earnings & ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? ...

SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to present and host investor meetings at the following investor conferences. Details of the presentations are as follow: Event: 2024 Wells Fargo Healthcare Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Wednesday, September 4, 2024 ...

FX Empire Logo English check-icon Italiano Español Português Deutsch العربية Français Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial ...

Halozyme Therapeutics, Inc. (HALO) reported second-quarter 2024 adjusted earnings of 91 cents per share, which surpassed the Zacks Consensus Estimate of 78 cents. The company had recorded earnings of 74 cents per share in the year-ago period. Total revenues increased almost 5% year over year to $231.4 million in the second quarter. Revenues surpassed the Zacks Consensus Estimate of $211 million. The top line was driven by higher royalty payments from Roche (RHHBY) for Phesgo and higher sales of proprietary ...